Biogen (BIIB) Tops Q3 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Biogen Reports Quarterly Revenues of $3.1 Billion
October 24, 2017 6:59 AM EDTTotal revenues grew 4% or 13% excluding hemophilia revenues*
GAAP diluted EPS rise 23%; Non-GAAP diluted EPS rise 22%
Company advances its strategic priorities
Company restructures collaboration arrangements with Eisai and Neurimmune to improve long-term value of aducanumab
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2017 financial results, including:
Total revenues of $3.1 billion, a 4% increase versus the prior year or a 13% increase excluding hemophilia revenues*. Multiple sclerosis (MS) revenues, including approximately $65... More